Literature DB >> 14736866

Direct evidence that toll-like receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosine-phosphate-guanine motif recognition.

Sylvie Cornélie1, Johan Hoebeke, Anne-Marie Schacht, Benjamin Bertin, Jérome Vicogne, Monique Capron, Gilles Riveau.   

Abstract

Cytosine-phosphate-guanine (CpG) motifs in bacterial DNA are known to activate the mammalian immune system, and this activation is thought to depend on the Toll-like receptor 9 (TLR9) signaling pathway. Previous studies strongly suggested that TLR9 is involved as the specific receptor for CpG motifs but did not provide direct evidence of their interaction. In this study, we demonstrate for the first time that murine TLR9 binds an unmethylated CpG-containing plasmid. This interaction is sequence-specific and is influenced by the methylation status of the plasmid. Furthermore, we demonstrate that this interaction leads to the activation of the NF-kappaB pathway in mTLR9-expressing cells. Our results provide a molecular basis for the interaction between CpG-DNA and TLR9.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14736866     DOI: 10.1074/jbc.M313406200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.

Authors:  Jörg Vollmer; Risini D Weeratna; Marion Jurk; Ulrike Samulowitz; Michael J McCluskie; Paul Payette; Heather L Davis; Christian Schetter; Arthur M Krieg
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

Review 2.  A proteomics perspective on viral DNA sensors in host defense and viral immune evasion mechanisms.

Authors:  Marni S Crow; Aaron Javitt; Ileana M Cristea
Journal:  J Mol Biol       Date:  2015-02-26       Impact factor: 5.469

Review 3.  Manifold mechanisms of Toll-like receptor-ligand recognition.

Authors:  Ken J Ishii; Cevayir Coban; Shizuo Akira
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

4.  The TLR3 signaling complex forms by cooperative receptor dimerization.

Authors:  Joshua N Leonard; Rodolfo Ghirlando; Janine Askins; Jessica K Bell; David H Margulies; David R Davies; David M Segal
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-02       Impact factor: 11.205

5.  CpG-oligodeoxynucleotide is a potent adjuvant with an Entamoeba histolytica Gal-inhibitable lectin vaccine against amoebic liver abscess in gerbils.

Authors:  Catherine P A Ivory; Kathy Keller; Kris Chadee
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

Review 6.  New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.

Authors:  Daniel J Wallace; Vineet S Gudsoorkar; Michael H Weisman; Swamy R Venuturupalli
Journal:  Nat Rev Rheumatol       Date:  2012-07-17       Impact factor: 20.543

7.  The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques.

Authors:  Yichuan Wang; Kristina Abel; Katherine Lantz; Arthur M Krieg; Michael B McChesney; Christopher J Miller
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

Review 8.  Traditional biochemical assays for studying toll-like receptor 9.

Authors:  Cynthia A Leifer; William A Rose; Fernando Botelho
Journal:  J Immunoassay Immunochem       Date:  2013

Review 9.  Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.

Authors:  Petar S Lenert
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

10.  Immunogenicity of intrathecal plasmid gene delivery: cytokine release and effects on transgene expression.

Authors:  Travis S Hughes; Stephen J Langer; Salla I Virtanen; Raymond A Chavez; Linda R Watkins; Erin D Milligan; Leslie A Leinwand
Journal:  J Gene Med       Date:  2009-09       Impact factor: 4.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.